Clinical evaluation observes subtype identification of primary aldosteronism during mineralocorticoid receptor blockade, suggesting a pathway to avoid severe hypokalemia.
Current guidelines and consensus documents recommend withdrawal of mineralocorticoid receptor antagonists (MRAs) before primary aldosteronism (PA) subtyping by adrenal vein sampling (AVS), but this practice can cause severe hypokalemia and uncontrolled high blood pressure. Our aim was to investigate if unilateral PA can be identified by AVS during MRA treatment.
No takes yet. Share an insight, caveat, or question.
Pintus et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: